Vicore Pharma Holding
Vicore Pharma: FPI Covid-19 (Redeye)
2020-07-28 07:15
Redeye reiterates its positive stance towards Vicore following the announcement of first Covid-19 patient being dosed in its phase II trial. We currently regard the Covid-19 indication as a bonus in our Base case, with considerable scope for re-valuation if results are proven encouraging. We expect top-line results from the trial already later this year.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se